Back to Interventions
Substance / Medication

Phenylbutazone

SNOMED 273951003UMLS C0031463

Overview

Active Ingredient
phenylbutazone
RxNorm CUI
8160

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Articular gout

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
1
Recruiting
0
With Results

Recent Trials

Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares

NCT07346079Phase 4Recruiting150 enrolled
View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Phenylbutazone induces equine glandular gastric disease without decreasing prostaglandin Econcentrations.
Pedersen S K, Cribb A E, Read E K et al. · J Vet Pharmacol Ther · 2018
PMID: 29148168RCT
Effects of Firocoxib, Flunixin Meglumine, and Phenylbutazone on Platelet Function and Thromboxane Synthesis in Healthy Horses.
Burkett Brenna N, Thomason John M, Hurdle Holly M et al. · Vet Surg · 2016
PMID: 27731498RCT
In vivo effects of phenylbutazone on inflammation and cartilage-derived biomarkers in equine joints with acute synovitis.
de Grauw J C, van Loon J P A M, van de Lest C H A et al. · Vet J · 2014
PMID: 24888681RCT
Effects of meloxicam and phenylbutazone on renal responses to furosemide, dobutamine, and exercise in horses.
Raidal Sharanne L, Hughes Kris J, Charman Amanda-Lee et al. · Am J Vet Res · 2014
PMID: 24959734RCT
Efficacy of single-dose intravenous phenylbutazone and flunixin meglumine before, during and after exercise in an experimental reversible model of foot lameness in horses.
Foreman J H, Grubb T L, Inoue O J et al. · Equine Vet J Suppl · 2010
PMID: 21059067RCT
A comparative study on the adverse effects of flunixin, ketoprofen and phenylbutazone in miniature donkeys: haematological, biochemical and pathological findings.
Mozaffari A A, Derakhshanfar A, Alinejad A et al. · N Z Vet J · 2010
PMID: 20927172RCT
Effects of top-dress formulations of suxibuzone and phenylbutazone on development of gastric ulcers in horses.
Andrews Frank M, Reinemeyer Craig R, Longhofer Susan L · Vet Ther · 2009
PMID: 20037965RCT
Effectiveness of administration of phenylbutazone alone or concurrent administration of phenylbutazone and flunixin meglumine to alleviate lameness in horses.
Keegan Kevin G, Messer Nat T, Reed Shannon K et al. · Am J Vet Res · 2008
PMID: 18241011RCT
The effects of chiropractic, massage and phenylbutazone on spinal mechanical nociceptive thresholds in horses without clinical signs.
Sullivan K A, Hill A E, Haussler K K · Equine Vet J · 2008
PMID: 18083655RCT
Effects of single-dose intravenous phenylbutazone on experimentally induced, reversible lameness in the horse.
Foreman J H, Barange A, Lawrence L M et al. · J Vet Pharmacol Ther · 2008
PMID: 18177317RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Phenylbutazone (substance)
SNOMED CT
273951003
UMLS CUI
C0031463
RxNorm CUI
8160

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.